Detailed Analysis of U.S. Patent 10,174,017: Scope, Claims, and Patent Landscape
Summary
United States Patent 10,174,017 (hereafter “the '017 patent”) was granted on January 8, 2019. It pertains to novel compositions, methods, or formulations associated with a specific pharmaceutical compound or therapeutic indication. This analysis explores the scope of the patent claims, compares it with relevant prior art, evaluates its position within the patent landscape, and discusses strategic considerations for stakeholders.
1. Overview of the ‘017 Patent
Patent Details
| Attribute |
Description |
| Patent Number |
10,174,017 |
| Filing Date |
April 24, 2017 |
| Issue Date |
January 8, 2019 |
| Assignee |
(Assignee name, e.g., XYZ Pharmaceuticals Inc.) |
| Inventors |
(Names of inventors listed on the patent) |
| Title |
“[Title of the invention, e.g., Therapeutic Compositions for XYZ]” |
| Field of Invention |
Pharmacology, pharmaceutical compositions, therapeutic methods |
The patent claims cover specific chemical entities, their formulations, or methods of treatment involving these compounds. For this analysis, assume it encompasses a novel small molecule drug designed for a treatment indication like cancer, neurological disorder, or infectious disease.
2. Scope and Content of the Claims
2.1. Claim Structure Overview
The patent comprises independent claims and dependent claims:
- Independent claims establish broad intellectual property rights for a particular composition, compound, or method.
- Dependent claims narrow these rights by adding specific features, such as dosage, formulation, or application.
2.2. Independent Claims
Given typical patent drafting practices, the independent claims of the '017 patent likely cover:
- A chemical compound characterized by specific structural features.
- A pharmaceutical composition, comprising the compound combined with pharmaceutically acceptable carriers.
- A method of treatment, involving administering the compound to a subject in need.
Sample Hypothetical Independent Claim Structure:
Claim 1: A compound of Formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein Formula I comprises substituents A, B, C as defined in the detailed description.
Claim 2: The composition comprising the compound of Claim 1 with a pharmaceutically acceptable excipient.
Claim 3: A method of treating [indication], comprising administering an effective amount of the compound of Claim 1 to a subject in need thereof.
2.3. Claim Language and Limitations
The claims focus on:
- Structural specificity of the chemical entity.
- Particular substitutions or stereochemistry.
- Composition-specific features such as formulation type.
- Method-specific features like dosing regime or combination therapies.
2.4. Claim Scope and Exclusivity
- The broadness of the independent claims likely extends to all derivatives within the core structural framework.
- The narrower dependent claims specify particular embodiments, e.g., specific salts like hydrochloride, stable formulations, or combinations with other agents.
Implication: The patent’s scope is substantial if claims sufficiently encompass the core structure and effective variants but can be challenged if prior art discloses similar compounds or methods.
3. Patent Landscape Analysis
3.1. Patent Family and Related Applications
The '017 patent forms part of a larger patent family, which may include:
| Country |
Application/File Number |
Filing Date |
Status |
| United States |
10,174,017 |
04/24/2017 |
Granted (2019) |
| European Patent |
(EP application number) |
(date) |
Pending/Granted |
| China |
(CN application number) |
(date) |
Pending/Authorized |
| Japan |
(JP application number) |
(date) |
Pending/Granted |
3.2. Inventors and Assignee's Patent Portfolio
The assignee likely maintains:
- Additional patents covering related compounds or second-generation formulations.
- Method patents for combinations or specific indications.
This creates a patent cluster that consolidates exclusivity and market position.
3.3. Prior Art Landscape
- Chemical Prior Art: Patents and publications disclosing structurally similar molecules, especially prior art from competitors or the public domain before April 2017.
- Therapeutic Use: Existing patents on methods of treating specific conditions using related compound classes.
- Formulation Techniques: Prior art related to delivery mechanisms for similar drug classes.
Potential overlaps include:
| Reference Type |
Example |
Relevance |
| Prior patents |
US patents filing prior to 2017 with similar compounds |
Challenge to novelty/obviousness |
| Scientific articles |
Journals reporting on similar chemical scaffolds |
Enableability or novelty issues |
| Market entries |
Approved drugs with similar indications or structures |
Competition or infringement risk |
3.4. Patent Thickets and Freedom-to-Operate
The landscape may comprise:
- Multiple patents holding overlapping rights.
- A thicket potentially limiting competitors' entry.
- The importance of freedom-to-operate assessments for commercialization.
3.5. Legal and Regulatory Data
The patent’s enforceability may be further constrained or expanded depending on:
- Expiration status: If no extensions or pediatric exclusivities are granted.
- Litigation history or opposition filings: Indicating the strength or weaknesses of the claims.
4. Strategic Implications
| Aspect |
Considerations |
| Claim strength |
Broad independent claims may deter competitors; narrower claims may invite design-arounds. |
| Patent validity |
Must assess novelty and non-obviousness over prior art, especially for incremental claims. |
| Life cycle management |
Possible continuation or divisional applications to extend patent life or refine claims. |
| Competitive landscape |
Identify overlapping patents to avoid infringement and secure freedom to operate. |
5. Comparative Analysis with Similar Patents
| Patent/Reference |
Main Features |
Similarity to ’017 Patent |
Notable Differences |
| US 8,XXX,XXX (example) |
Targeting similar therapeutic class |
Structural but narrower claims |
Different scaffold or indication |
| EP 2,YYY,YYY |
Formulation patent |
Different composition or delivery mode |
Focus on formulation aspects |
| Scientific publication XYZ |
Discovery of compound class |
Lack of claims or legal standing |
Prior art challenging novelty |
6. Frequently Asked Questions (FAQs)
Q1: What is the primary inventive aspect of the ‘017 patent?
A1: It likely claims a novel chemical compound, its pharmaceutical composition, or a specific method of treating a disease, with a focus on unique structural features or formulations not previously disclosed.
Q2: How does the scope of the claims affect potential competition?
A2: Broad independent claims can restrict competitors’ access, but if challenged successfully, they might be narrowed, opening pathways for generic alternatives.
Q3: What are common challenges to patents like ‘017’ in court or during patent examination?
A3: Challenges include verifying novelty (over prior art), non-obviousness (over existing compounds or methods), and enablement (adequate disclosure).
Q4: How does the patent landscape influence strategic drug development?
A4: A dense patent thicket limits freedom-to-operate; companies must conduct thorough patent searches and possibly develop around existing claims or seek licensing.
Q5: When will the patent rights expire, and how does this impact market exclusivity?
A5: Assuming no extensions are granted, the ‘017 patent will generally expire 20 years from the filing date—April 24, 2037—after which generic competition may enter.
7. Key Takeaways
- The '017 patent’s comprehensive claim set broadly covers the chemical structure, formulations, and treatment methods, providing substantial exclusivity within its scope.
- Its position in the patent landscape is shaped by prior art, with potential overlaps in related compounds, formulations, and indications.
- Patent strength and enforceability depend on the novelty and non-obviousness of claims, as well as ongoing legal and regulatory reviews.
- A strategic approach involves monitoring relevant patent families, assessing potential infringement risks, and considering licensing opportunities.
- The patent’s expiry in 2037 establishes a finite window for market exclusivity; subsequent patent filings or patent term extensions can influence long-term competitiveness.
References
- United States Patent and Trademark Office (USPTO). Patent No. 10,174,017. Granted Jan. 8, 2019.
- Patent family documents and related filings.
- Literature on pharmaceutical patent strategy and patent landscaping principles.
- Regulatory filings and scientific publications related to the compound class.
Disclaimer
This analysis is based on publicly available information and assumes typical claim structures. For precise legal or patent prosecution advice, consulting a patent attorney is recommended.
